MIRA INFORM REPORT

Report Date :

01.03.2012

IDENTIFICATION DETAILS

Name :	OBSONS PHARMACEUTICALS

Registered Office :	209-S, Industrial Estate, Kot Lakhpat, Lahore

Country :	Pakistan

Year of Establishment :	2002

Legal Form :	Partnership Concern

Line of Business :	Manufacture & Marketing of Pharmaceutical Products

No. of Employees :	115

RATING & COMMENTS

MIRA’s Rating :

RATING		STATUS	PROPOSED CREDIT LINE
41-55	Ba	Overall operation is considered normal. Capable to meet normal commitments.	Satisfactory

Status :	Satisfactory

Payment Behaviour :	No Complaints

Litigation :	Clear

NOTES:

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

ECGC Country Risk Classification List – September 30^th, 2011

Country Name

Previous Rating

(30.06.2011)

Current Rating

(30.09.2011)

Pakistan

Risk Category	ECGC Classification
Insignificant	A1
Low	A2
Moderate	B1
High	B2
Very High	C1
Restricted	C2
Off-credit	D

Business Name

OBSONS PHARMACEUTICALS

Full Address

Registered Address & Factory

209-S, Industrial Estate, Kot Lakhpat, Lahore, Pakistan

Tel #	92 (42) 35153572, 35142172
Fax #	92 (42) 35142172
Email	blf_tahir@yahoo.com

Short Description Of Business

a.	Nature of Business	Manufacture & Marketing of Pharmaceutical Products
b.	Year Established	2002

branches

Is Located at Lahore

Legal Status

Subject Concernwas established as a Partnership business in 2002

Details of Managing Partner / Partners

Names

Nationality

Address

Occupation

Designation

Mr. Sheikh M. Habibullah

Mr. S.M. Inamullah

Pakistani

209-S, Industrial Estate, Kot Lakhpat, Lahore

Business

Managing Partner

Partner

Associates

A. Subsidiary

None

B. Associated Companies

- Do -

Products

(1) Subject Concernis engaged in manufacture & marketing of Pharmaceutical Products by its brand names of APHYLIN, AZEE-VIT, AZROCIN, CIPCIN, DECOREX, EVERBACT, HAEMOGEN, HALRIN, LATADINE, MEPROL, NIROX, OBATIDINE, OBENDAZOLE, OBITRAN, OBLAC, OBLONEC, OBNACK, OBSODINE, OBSOZOLE, OBVASTIN, OBZOLE, OFCIN, OFTAG, ORTIZIN, PROALPHA, RUBINOL, SINOPRIL, SPARTATE, TUZFEN, ULFATE, VINCAM, VINZOLE.

(2) It purchases raw material against D/A, D/P basis.

(3) Its’ major customers are Distributors, Traders, Pharmacies & Hospitals located at major cities of Punjab Province.

(4) Subject operates from caption leased factory premises of area measuring 6,000 Sq.Yard which is situated at industrial area of Lahore.

(5) Subject employs about 115 persons in its set up.

Annual Sales Volume

Year	In Pak Rupees
2010	60,000,000/- (Estimated)

Capacity & Production

The capacity and production of the company’s plant is indeterminable as it is multi- product and involves various processes of manufacture.

Trade Suppliers

(Foreign)

· (1) AARTI DRUGS, INDIA.

· (2) ROQUETTE INTERNATIONAL, FRANCE.

· (3) NORTH CHINA PHARMACEUTICAL GROUP, CHINA.

Bankers

· Soneri Bank Limited, Pakistan.

· Habib Bank Limited, Pakistan.

· Allied Bank Limited, Pakistan.

· Bank Alfalah Limited, Pakistan.

Memberships

· Lahore Chamber of Commerce & Industry.(LCCI)

· Pakistan Pharmaceutical Manufacturers Association.(PPMA)

Foreign Exchange Rates

Currency	Unit	Pakistani Rupee
US Dollar	1	Rs. 90.90
UK Pound	1	Rs. 143.50
Euro	1	Rs. 119.80

Comments

Subject Concernwas established in 2002 and is engaged in manufacture & marketing of Pharmaceutical Products. Trade relations are reported as fair. Subject can be considered for normal business dealings at usual trade terms and conditions.

FOREIGN EXCHANGE RATES

Currency	Unit	Indian Rupees
US Dollar	1	Rs.48.94
UK Pound	1	Rs.77.95
Euro	1	Rs.65.94

RATING EXPLANATIONS

RATING		STATUS	PROPOSED CREDIT LINE
>86	Aaa	Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums	Unlimited
71-85	Aa	Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums	Large
56-70	A	Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums	Fairly Large
41-55	Ba	Overall operation is considered normal. Capable to meet normal commitments.	Satisfactory
26-40	B	Capability to overcome financial difficulties seems comparatively below average.	Small
11-25	Ca	Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity	Limited with full security
<10	C	Absolute credit risk exists. Caution needed to be exercised	Credit not recommended
----	NB	New Business	----

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

Financial condition (40%) Ownership background (20%) Payment record (10%)

Credit history (10%) Market trend (10%) Operational size (10%)

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.